ENTRESTO® (sacubitril/valsartan) was granted an expanded indication by the FDA. ENTRESTO is now approved to reduce the risk of cardiovascular death and heart failure hospitalization in more adult patients with chronic heart failure (CHF). Benefits … [Read more...]